
Aevius, a healthcare AI startup, has raised $22 million in funding led by Insight Partners to develop its clinical intelligence technology and expand its commercial operations.
The company will use the new funding to improve its AI models and products, expand its engineering, clinical, and commercial teams, and accelerate the commercial deployment of its technology.
“Our mission is to make medicine computable,” said Rowland Pettit, M.D., Ph.D., co-founder and chief executive officer of Aevius. “As a physician-scientist, I’ve worked across many types of clinical data, and there is far more knowledge in those records than we’re able to use today. We’re bringing general medical intelligence to that data, so organizations can build on a deeper understanding for their patients.”
Founded by Rowland Pettit, Ming Yang (Max) Lu, Faisal Mahmood, and Long Phi Le, Aevius develops AI models that help healthcare organizations turn complex medical data into useful insights. The founding team previously worked at Modella AI, a medical AI company acquired by AstraZeneca.
Aevius focuses on making medical information easier to understand and use. Healthcare organizations store large amounts of patient information across electronic health records, medical documents, clinical reports, and other systems. However, this information is often difficult to combine and analyze because it exists in different formats and systems.
“Most AI agents today piece together their picture of a patient from text, one question at a time,” said Ming Yang (Max) Lu, Ph.D., co-founder and chief technology officer of Aevius. “We’re building a native representation of each patient’s multimodal, longitudinal history that powers prediction and analysis across an entire population. Researchers, care teams and AI agents can take on new questions without starting over, working from the whole patient rather than fragments of a record.”
“The value of medical AI will be measured by how well it promotes accuracy,” said Eric Topol, M.D., chair of Aevius’s Scientific Advisory Board. “Aevius is pursuing that goal with models grounded in the breadth and complexity of patients’ medical histories.”
The company’s AI models analyze structured, unstructured, and multimodal medical data to create detailed representations of patients’ health conditions and medical histories. These representations can be updated as new patient information becomes available, helping healthcare teams and AI tools make better-informed decisions.
The technology can support several healthcare applications, including predicting patient outcomes, identifying patients with similar medical conditions, monitoring disease progression, and identifying groups of patients who may need specific treatments.
Aevius is developing solutions for hospitals and health systems, health insurance providers, and life sciences companies.
For healthcare providers, its technology can support clinical research, patient care planning, and hospital resource management. Insurance companies can use the platform to better understand patient needs and support earlier, more coordinated care.
For pharmaceutical and life sciences companies, Aevius aims to improve clinical research by helping researchers understand disease progression, identify potential biomarkers, and find suitable patients for clinical trials.
Aevius is a spinout from Mass General Brigham, a healthcare and research organization. With its latest $22 million investment, the company plans to strengthen its AI technology and expand its presence across the healthcare and life sciences industries.